Quinoline derivatives as kinase inhibitors
US8637543B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 11, 2010 |
| Grant date | Jan 28, 2014 |
| Priority date | — |
| Expiry date | Jan 23, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.